{"filing":{"accession_number":"0001104659-26-082897","cik":"0001372299","ticker":"OCGN","company_name":"Ocugen, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"tm2620295d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_8k.htm"},"events":[{"id":17509,"run_id":15683,"accession_number":"0001104659-26-082897","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Ocugen announced a binding term sheet to license OCU400 for retinitis pigmentosa in the Middle East and North Africa region, with cumulative sales milestones up to $255 million, upfront/development payments up to $4 million, and 22% royalties on net sales. This is a material strategic partnership and licensing arrangement that expands the company's geographic reach and revenue potential, but does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control). The event is clearly operational/strategic in nature—a significant commercial partnership—rather than fitting the specific M\u0026A definition.","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16010,"accession_number":"0001104659-26-082897","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ocugen announced a binding term sheet to license OCU400 for retinitis pigmentosa in the Middle East and North Africa region, with cumulative sales milestones up to $255 million, upfront/development payments up to $4 million, and 22% royalties on net sales. This is a material strategic partnership and licensing arrangement that expands the company's geographic reach and revenue potential, but does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control). The event is clearly operational/strategic in nature—a significant commercial partnership—rather than fitting the specific M\u0026A definition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:31:39.334541+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16010,"accession_number":"0001104659-26-082897","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ocugen announced a binding term sheet to license OCU400 for retinitis pigmentosa in the Middle East and North Africa region, with cumulative sales milestones up to $255 million, upfront/development payments up to $4 million, and 22% royalties on net sales. This is a material strategic partnership and licensing arrangement that expands the company's geographic reach and revenue potential, but does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control). The event is clearly operational/strategic in nature—a significant commercial partnership—rather than fitting the specific M\u0026A definition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:31:39.334541+00:00","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-07-13"}]}